Peter Venner

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

F. Saad, A. Kapoor, S. Hotte, 2011, Current oncology.

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

D. Osoba, I. Tannock, K. Murphy, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.

D. Osoba, J. Pater, J. Latreille, 1992, European journal of cancer.

A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy.

K. Graham, S. North, P. Venner, 2006, The Journal of urology.

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.

F. Saad, S. Hotte, S. Sridhar, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Placebo‐associated remissions in a multicentre, randomized, double‐blind trial of interferon γ‐1b for the treatment of metastatic renal cell carcinoma

M. Gleave, F. Saad, M. Elhilali, 2000 .